Ghrelin ameliorates acute lung injury induced by oleic acid via inhibition of endoplasmic reticulum stress.

Tian X, Liu Z, Yu T, Yang H, Feng L

Life sciences24 Jul 2017Cited by 12 (Europe PMC)

PMID28751159DOI10.1016/j.lfs.2017.07.023PepBankPUB-28751159

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

01AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated pulmonary injury.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened lung injury compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreasePulmonary injury
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Lung injury and fibrosis · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115901
02AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated pulmonary edema.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened lung edema compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreasePulmonary edema
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Lung injury and fibrosis · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115902
03AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated inflammatory cellular infiltration.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened inflammatory cell infiltration compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreaseInflammatory cellular infiltration
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115903
04AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated cytokine release.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened cytokine release compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreaseCytokine release
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115904
05AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated hypoxia.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened low oxygen compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreaseHypoxia
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Respiratory function · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115905
06AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Efficacy outcome
In rats with oleic acid injury, antagonist treatment including D-Lys-GHRP‑6 exacerbated carbon dioxide retention.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 worsened carbon dioxide retention compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreaseCarbon dioxide retention
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Respiratory function · Respiratory
Source sentences
Summary
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
2 context sentences(design, population, supporting numbers)
Summary · context
Rats with OA treatment showed significant pulmonary injury, edema, inflammatory cellular infiltration, cytokine release, hypoxia and CO₂ retention as compared with controls.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115906
07AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In rats with oleic acid injury, ghrelin antagonist treatment including D-Lys-GHRP‑6 augmented endoplasmic reticulum stress.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 increased cellular stress compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
IncreaseEndoplasmic reticulum stress
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Receptor activity and mechanism · Respiratory
Source sentences
Summary
ERS induced by OA was prevented by ghrelin and augmented by ghrelin antagonist treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115907
08AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism
In rats with oleic acid injury, ghrelin antagonists including D-Lys-GHRP‑6 further exacerbated the decreased p-Akt/Akt ratio.
In plain wordsIn rats, antagonists including D-Lys-GHRP‑6 further reduced the p-Akt/Akt ratio compared with oleic acid injury without antagonist treatment.
Peptide
GHRP-6
Outcome
Decreasep-Akt/Akt ratio
Study
ratn: not reported in source
oleic acid-induced acute lung injury
Comparator
Oleic acid injury without antagonist treatment
Outcome group
Receptor activity and mechanism · Respiratory
Source sentences
Summary
The decreased ratio of p-Akt and Akt induced by OA was improved by ghrelin treatment, and was further exacerbated by ghrelin antagonists.
2 context sentences(design, population, supporting numbers)
Summary · context
Ghrelin (10nmol/kg) treatment ameliorated the above symptoms, but treatment with the ghrelin antagonists D-Lys³ GHRP-6 (1μmol/kg) and JMV 2959 (6mg/kg) exacerbated the symptoms.
Summary · context
We used a rat oleic acid (OA)-induced ALI model.
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-2875115908

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.